These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 30910864)

  • 61. Uniting Latin America Through Research: How Regional Research Can Strengthen Local Policies, Networking, and Outcomes for Patients With Lung Cancer.
    Arrieta O; Zatarain-Barrón ZL; Cardona AF; Corrales L; Martin C; Cuello M
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-7. PubMed ID: 35503985
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Companion diagnostics and molecular imaging-enhanced approaches for oncology clinical trials.
    Van Heertum RL; Scarimbolo R; Ford R; Berdougo E; O'Neal M
    Drug Des Devel Ther; 2015; 9():5215-23. PubMed ID: 26392755
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Personalizing oncology: perspectives and prospects.
    Mendelsohn J
    J Clin Oncol; 2013 May; 31(15):1904-11. PubMed ID: 23589547
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Initiative for Molecular Profiling and Advanced Cancer Therapy and challenges in the implementation of precision medicine.
    Tsimberidou AM
    Curr Probl Cancer; 2017; 41(3):176-181. PubMed ID: 28410846
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Application of molecular profiling in clinical trials for advanced metastatic cancers.
    Kummar S; Williams PM; Lih CJ; Polley EC; Chen AP; Rubinstein LV; Zhao Y; Simon RM; Conley BA; Doroshow JH
    J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25663694
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The global conduct of cancer clinical trials: challenges and opportunities.
    Barrios CH; Werutsky G; Martinez-Mesa J
    Am Soc Clin Oncol Educ Book; 2015; ():e132-9. PubMed ID: 25993164
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.
    Schmidt KT; Chau CH; Price DK; Figg WD
    J Clin Pharmacol; 2016 Dec; 56(12):1484-1499. PubMed ID: 27197880
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine.
    Tsimberidou AM; Hong DS; Wheler JJ; Falchook GS; Janku F; Naing A; Fu S; Piha-Paul S; Cartwright C; Broaddus RR; Nogueras Gonzalez GM; Hwu P; Kurzrock R
    J Hematol Oncol; 2019 Dec; 12(1):145. PubMed ID: 31888672
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Art and Challenges of Precision Medicine: Interpreting and Integrating Genomic Data Into Clinical Practice.
    Madhavan S; Subramaniam S; Brown TD; Chen JL
    Am Soc Clin Oncol Educ Book; 2018 May; 38():546-553. PubMed ID: 30231369
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Globalization of pediatric research: pharmacological RCTs in Latin America.
    Arienti F; Pansieri C; Pandolfini C; Biondi A; Bonati M
    Ital J Pediatr; 2019 Mar; 45(1):29. PubMed ID: 30832712
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Making precision oncology the standard of care.
    The Lancet Oncology
    Lancet Oncol; 2017 Jul; 18(7):835. PubMed ID: 28677559
    [No Abstract]   [Full Text] [Related]  

  • 72. Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials.
    Hyman DM; Solit DB; Arcila ME; Cheng DT; Sabbatini P; Baselga J; Berger MF; Ladanyi M
    Drug Discov Today; 2015 Dec; 20(12):1422-8. PubMed ID: 26320725
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Defining, Identifying, and Understanding "Exceptional Responders" in Oncology Using the Tools of Precision Medicine.
    Tsimberidou AM; Said R; Staudt LM; Conley BA; Takebe N
    Cancer J; 2019; 25(4):296-299. PubMed ID: 31335394
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Synthetic lethality-mediated precision oncology via the tumor transcriptome.
    Lee JS; Nair NU; Dinstag G; Chapman L; Chung Y; Wang K; Sinha S; Cha H; Kim D; Schperberg AV; Srinivasan A; Lazar V; Rubin E; Hwang S; Berger R; Beker T; Ronai Z; Hannenhalli S; Gilbert MR; Kurzrock R; Lee SH; Aldape K; Ruppin E
    Cell; 2021 Apr; 184(9):2487-2502.e13. PubMed ID: 33857424
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Global Challenges in Access to and Implementation of Precision Oncology: The Health Care Manager and Health Economist Perspective.
    Shih YT; Pan IW; Teich N
    Am Soc Clin Oncol Educ Book; 2022 Jul; 42():429-437. PubMed ID: 35829692
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Clonotyping for precision oncology.
    Dang HX; Maher CA
    Drug Discov Today; 2015 Dec; 20(12):1464-9. PubMed ID: 26494143
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development.
    Bando H; Takebe N
    Jpn J Clin Oncol; 2015 Nov; 45(11):1001-6. PubMed ID: 26423340
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Budget impact and cost-effectiveness: can we afford precision medicine in oncology?
    Doble B
    Scand J Clin Lab Invest Suppl; 2016; 245():S6-S11. PubMed ID: 27426412
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Conference scene: Latin American Pharmacogenomics and Personalized Medicine Conference.
    Suarez-Kurtz G
    Pharmacogenomics; 2012 Oct; 13(13):1449-52. PubMed ID: 23057544
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The landscape of precision cancer medicine clinical trials in the United States.
    Roper N; Stensland KD; Hendricks R; Galsky MD
    Cancer Treat Rev; 2015 May; 41(5):385-90. PubMed ID: 25864024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.